EGFR Mutant NSCLC: Expert Perspectives in Testing and Targeted Therapy

After a brief introduction, Lyudmila Bazhenova, MD reviews treatment options for early-stage NSCLC, the prevalence of EGFR mutations, and guidelines for managing patients with stage 1b resectable disease.

The panelists explore the groundbreaking ADAURA trial, covering its study design, efficacy and safety results, and the current clinical implications.

Analyzing a recent overall survival analysis from the ADAURA trial, its impact on practice, and changes in the treatment landscape of early NSCLC.

Recommendations for community oncologists concerning molecular testing, including the types of tests, timing best practices, and how the results should inform treatment decisions.

On the subject of patient eligibility, the panel deliberates on the decision-making process between osimertinib and chemotherapy and outlines adjuvant therapy options.

Insights on the use of neoadjuvant therapy in resectable NSCLC, particularly focusing on the use of neoadjuvant IO in EGFR mutated patients and the results of relevant trials.